INVA

Innoviva, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001080014
$22.74 +1.34% $1.7B
19 New Institutional Positions9 Institutional Exits
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders50 funds
Inst. Value$1.2B
Inst. Activity19 buys / 9 sells
Reddit Sentiment67° Warm
SEC Reports3
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001080014·Prev Close $22.44

Recent Activity

May 22, 2026 short_volume
Short Volume: INVA — 82.1% short (0.6M / 0.7M)
Short: 589,297 | Exempt: 223,800 | TRF Vol: 717,911 | Short Ratio: 82.1% | Off-exchange volume (dark
May 20, 2026 Insider
Raifeld Pavel surrendered for taxes 1,130 shares
Chief Executive Officer @ $22.24 ($25.1K)
May 20, 2026 Insider
Zhen Marianne surrendered for taxes 1,127 shares
Chief Accounting Officer @ $22.24 ($25.1K)
May 20, 2026 Insider
Basso Stephen surrendered for taxes 559 shares
Chief Financial Officer @ $22.24 ($12.4K)
May 18, 2026 SEC
Innoviva reported the resignations of board members Derek Small and Mark DiPaolo to focus on their roles at Syndeio BioS
8-K — Impact 3/10
May 6, 2026 SEC
Innoviva reported Q1 2026 total revenue of $98.0M (+11% YoY, slightly below $101.6M consensus) and diluted EPS of $2.22,
8-K — Impact 5/10
Mar 27, 2026 SEC
Innoviva, Inc. filed an amended 10-K to include the audited consolidated financial statements of its majority-owned subs
10-K/A — Impact 3/10
Inst.
DZ BANK AG Deutsche — ADD
892,336 shares ($20.8M)

Price Targets

$35.50 +56.1% upside Strong Buy
Current $22.74 Low $18.00 Median $39.00 High $46.00 4 analysts
$18.00 $46.00

Analyst Ratings

Strong Buy82% buy · 11 analysts
4Strong Buy
5Buy
1Hold
1Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 1, 2026 HC Wainwright & Co. REITERATE Buy → Buy
May 26, 2026 BTIG REITERATE Buy → Buy
May 7, 2026 BTIG MAINTAIN Buy → Buy
Feb 26, 2026 BTIG REITERATE Buy → Buy
Feb 17, 2026 BTIG INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.50 $0.50 — $0.50 1
Next Q $0.46 $0.46 — $0.46 20% YoY 1
Current FY $1.91 $1.91 — $1.91 2% YoY 1
Next FY $2.21 ▼ -3.3% $2.21 — $2.21 16% YoY 1

Top Institutional Holders

FundValueMove
BlackRock, Inc.$263.5M
DIMENSIONAL FUND ADVISORS LP$103.4M
VANGUARD PORTFOLIO MANAGEMENT LLC$98.4M
RENAISSANCE TECHNOLOGIES LLC$94.5M
VANGUARD CAPITAL MANAGEMENT LLC$73.2M

Recent Insider Trades

DateInsiderTypeValue
May 20, 2026Raifeld PavelF$25.1K
May 20, 2026Zhen MarianneF$25.1K
May 20, 2026Basso StephenF$12.4K
May 18, 2026Linden JosephineA$0.00
May 18, 2026Linden JosephineA$0.00

Reddit Sentiment

67°
Warm
Bearish Neutral Bullish
2 mentions 2 bullish 0 bearish
50 institutional holders with $1.2B total value (52,867,765 shares) as of 2026-Q1. Top holders: BlackRock,, DIMENSIONAL, VANGUARD. Net buying activity: 19 institutions added/increased vs 9 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BlackRock, Inc.11,307,845$263.5M21.4%
2DIMENSIONAL FUND ADVISORS LP4,436,427$103.4M8.4%
3VANGUARD PORTFOLIO MANAGEMENT LLC4,224,951$98.4M8.0%
4RENAISSANCE TECHNOLOGIES LLC4,055,632$94.5M7.7%
5VANGUARD CAPITAL MANAGEMENT LLC3,141,581$73.2M5.9%
6STATE STREET CORP3,060,377$71.3M5.8%
7ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1,887,570$44.0M3.6%
8BANK OF AMERICA CORP /DE/1,619,994$37.7M3.1%
9GOLDMAN SACHS GROUP INC1,593,383$37.1M3.0%
10MARSHALL WACE, LLP1,504,411$35.1M2.8%
11TWO SIGMA INVESTMENTS, LP1,484,264$34.6M2.8%ADD +60.8%
12MORGAN STANLEY1,310,750$30.5M2.5%
13CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,163,713$27.1M2.2%
14ROYCE & ASSOCIATES LP1,061,448$24.7M2.0%ADD +81.9%
15DEUTSCHE BANK AG\908,067$21.2M1.7%
16Invesco Ltd.904,282$21.1M1.7%
17DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main892,336$20.8M1.7%ADD +28.0%
18Nuveen, LLC620,482$14.5M1.2%TRIM -53.5%
19WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC574,825$13.4M1.1%NEW
20VICTORY CAPITAL MANAGEMENT INC523,415$12.2M1.0%ADD +42.2%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am MainADD696,911892,336+28.0%$20.8M2026-Q1
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCNEW574,825$13.4M2026-Q1
VICTORY CAPITAL MANAGEMENT INCADD368,000523,415+42.2%$12.2M2026-Q1
Allianz Asset Management GmbHADD336,904519,017+54.1%$12.1M2026-Q1
BALYASNY ASSET MANAGEMENT L.P.ADD244,030322,009+32.0%$7.5M2026-Q1
FIRST TRUST ADVISORS LPDOUBLED118,622278,340+134.6%$6.5M2026-Q1
FRANKLIN RESOURCES INCNEAR_EXIT1,392,341257,607-81.5%$6.0M2026-Q1
VOLORIDGE INVESTMENT MANAGEMENT, LLCTRIM481,821234,359-51.4%$5.5M2026-Q1
AMERIPRISE FINANCIAL INCADD144,998192,799+33.0%$4.5M2026-Q1
NOMURA HOLDINGS INCTRIM246,545144,087-41.6%$3.4M2026-Q1
SEI INVESTMENTS COADD87,063131,205+50.7%$3.1M2026-Q1
Universal- Beteiligungs- und Servicegesellschaft mbHTRIM173,119115,021-33.6%$2.7M2026-Q1
HSBC HOLDINGS PLCTRIM323,646101,608-68.6%$2.4M2026-Q1
QRG CAPITAL MANAGEMENT, INC.ADD79,704101,311+27.1%$2.4M2026-Q1
JENNISON ASSOCIATES LLCADD46,40369,767+50.4%$1.6M2026-Q1
FMR LLCDOUBLED29,03268,730+136.7%$1.6M2026-Q1
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDNEAR_EXIT330,75768,000-79.4%$1.6M2026-Q1
LOS ANGELES CAPITAL MANAGEMENT LLCNEAR_EXIT253,10453,533-78.8%$1.2M2026-Q1
HighTower Advisors, LLCADD26,12835,595+36.2%$829.4K2026-Q1
ENVESTNET ASSET MANAGEMENT INCDOUBLED11,42532,470+184.2%$756.6K2026-Q1
Cerity Partners LLCADD13,68824,327+77.7%$566.8K2026-Q1
AmundiTRIM46,82421,940-53.1%$511.2K2026-Q1
FIFTH THIRD BANCORPDOUBLED62117,038+2643.6%$397.0K2026-Q1
Mariner, LLCADD11,66215,408+32.1%$359.0K2026-Q1
CWM, LLCADD9,03714,060+55.6%$327.6K2026-Q1
8 unique insiders with 24 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 20, 2026Raifeld PavelChief Executive OfficerTAX W/H1,130$22.24$25.1K
May 20, 2026Zhen MarianneChief Accounting OfficerTAX W/H1,127$22.24$25.1K
May 20, 2026Basso StephenChief Financial OfficerTAX W/H559$22.24$12.4K
May 18, 2026Linden JosephineDirectorAWARD5,733
May 18, 2026Linden JosephineDirectorAWARD9,166
May 15, 2026Raifeld PavelChief Executive OfficerAWARD1,123
May 15, 2026Basso StephenChief Financial OfficerAWARD1,123
May 4, 2026DiPaolo MarkDirectorAWARD9,786
May 4, 2026Haimovitz JulesDirectorAWARD9,786
May 4, 2026Small Derek ADirectorAWARD10,000
May 4, 2026Basso StephenChief Financial OfficerAWARD93,750
May 4, 2026Schlesinger Sarah J.DirectorAWARD10,000
May 4, 2026Zhen MarianneChief Accounting OfficerAWARD31,500
May 4, 2026Raifeld PavelChief Executive OfficerAWARD312,500
May 4, 2026DiPaolo MarkDirectorAWARD10,000
May 4, 2026Haimovitz JulesDirectorAWARD10,000
May 4, 2026Zhen MarianneChief Accounting OfficerAWARD12,766
May 4, 2026Raifeld PavelChief Executive OfficerAWARD126,646
May 4, 2026Small Derek ADirectorAWARD9,786
May 4, 2026Basso StephenChief Financial OfficerAWARD37,994
May 4, 2026Schlesinger Sarah J.DirectorAWARD9,786
Feb 20, 2026Raifeld PavelChief Executive OfficerTAX W/H2,986$23.39$69.8K
Feb 20, 2026Basso StephenChief Financial OfficerTAX W/H1,244$23.39$29.1K
Feb 20, 2026Zhen MarianneChief Accounting OfficerTAX W/H2,460$23.39$57.5K

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 4 strong buy, 5 buy, 1 hold, 1 sell, 0 strong sell.

Analyst Price Targets

$35.50 mean target +56.1% upside Strong Buy (2.00)
$18.00 Low $46.00 High
MetricValue
Current Price$22.74
Target Low$18.00
Target Mean$35.50
Target Median$39.00
Target High$46.00
# Analysts4
RecommendationStrong Buy (2.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$0.50 $0.50 $0.50 +0.0% 1↑ 1↓ $0.1B 10.7% 1
Next Q
2026-09-30
$0.46 $0.46 $0.46 19.6% +0.0% 0↑ 1↓ $0.1B 5.3% 1
Current FY
2026-12-31
$1.91 $1.91 $1.91 1.9% +0.0% 1↑ 1↓ $0.4B 7.1% 1
Next FY
2027-12-31
$2.21 $2.21 $2.21 15.7% -3.3% 0↑ 2↓ $0.5B 10.3% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.500
7d ago$0.500
30d ago$0.500
60d ago$0.500
90d ago$0.535-0.035
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 1, 2026 HC Wainwright & Co. REITERATE Buy Buy
May 26, 2026 BTIG REITERATE Buy Buy
May 7, 2026 BTIG MAINTAIN Buy Buy
Feb 26, 2026 BTIG REITERATE Buy Buy
Feb 17, 2026 BTIG INITIATE Buy
Dec 16, 2025 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264511082%
May 1, 20264511082%
Apr 1, 20264511082%
Mar 1, 20264511082%
Feb 1, 20263511080%
Jan 1, 20263511080%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

67°
Warm
Bearish Neutral Bullish
2 mentions 2 bullish 0 bearish 2 time periods

Reddit Sentiment History

DateMentionsSentimentBullishBearishThreads
Apr 22, 2026160° Warm101
Apr 22, 2026160° Warm101

Recent Reddit Threads

r/options Bullish 1mo ago
Plenty of good opportunities, but no volume / open interest
▲ 1 💬 0 ⚡ 0.5
May 22, 2026
short_volume
Short Volume: INVA — 82.1% short (0.6M / 0.7M)
Short: 589,297 | Exempt: 223,800 | TRF Vol: 717,911 | Short Ratio: 82.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
INVA Q1 2026 Earnings Scheduled — 2026-05-13
May 5, 2026
earnings_calendar
INVA Q1 2026 Earnings Scheduled — 2026-05-05
Mar 4, 2026
earnings_calendar
INVA Q4 2025 Earnings After Market Close — 2026-03-04
Dec 15, 2025
fda_pdufa
PDUFA: INVA — zoliflodacin in uncomplicated gonorrhea in adults and pediatric patients 12 years and older — 2025-12-15
FDA target action date 2025-12-15 for INVA (Innoviva, Inc.). Drug: zoliflodacin. Indication: uncomplicated gonorrhea in adults and pediatric patients